Mr. Yash Gupta - Equity Research Associate, Angel Broking Ltd
"Sun Pharma Advanced Research Company Ltd. reported positive top-line results from its Phase 3 trial for its investigational drug, SDN-037, for the treatment of Inflammation and Pain associated with Ocular Surgery. The trial met its prespecified primary and secondary objectives, demonstrating that SDN-037 is superior to its vehicle. The objective of the trial was to assess the efficacy and safety of SDN-037 in clearing the inflammation and pain. A key secondary endpoint was the proportion of subjects with a visual analog scale (VAS) pain score of zero (0) at Day 15, and this was also statistically significant in patients treated with SDN-037 compared to vehicle. SDN-037 is a novel, twice-a-day, clear, micellar formulation of difluprednate. SDN-037 is 0.04% difluprednate ophthalmic solution with lower dose (i.e. 0.04% w/v) and reduced dosing frequency (twice-a-day) compared to currently commercialized formulation of difluprednate. This is positive development for the company."
Shares of SUN PHARMA ADVANCED RESEARCH COMPANY LTD. was last trading in BSE at Rs.172.45 as compared to the previous close of Rs. 169.35. The total number of shares traded during the day was 52419 in over 1416 trades.
The stock hit an intraday high of Rs. 173.2 and intraday low of 168.5. The net turnover during the day was Rs. 8972616.